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Cervical artery dissection (CeAD), a mural hematoma in a 
carotid or vertebral artery, is a major cause of ischemic stroke 
in young adults although relatively uncommon in the general 
population (incidence of 2.6/00,000 per year). Minor 
cervical traumas, infection, migraine and hypertension are 
putative risk factors–3, and inverse associations with obesity 
and hypercholesterolemia are described3,4. No confirmed 
genetic susceptibility factors have been identified using 
candidate gene approaches5. We performed genome-wide 
association studies (GWAS) in ,393 CeAD cases and 4,46 
controls. The rs9349379[G] allele (PHACTR1) was associated 
with lower CeAD risk (odds ratio (OR) = 0.75, 95% confidence 
interval (CI) = 0.69–0.82; P = 4.46 × 0−0), with confirmation 
in independent follow-up samples (659 CeAD cases and 2,648 
controls; P = 3.9 × 0−3; combined P = .00 × 0−). The 
rs9349379[G] allele was previously shown to be associated 
with lower risk of migraine and increased risk of myocardial 
infarction6–9. Deciphering the mechanisms underlying this 
pleiotropy might provide important information on the 
biological underpinnings of these disabling conditions.
We organized an international initiative with the aim of collecting clinical 
data and DNA for the largest possible number of CeAD cases to identify 
genetic susceptibility loci. We obtained 942 CeAD cases from the 
Cervical Artery Dissections and Ischemic Stroke Patients (CADISP) 
study (CADISP-1: 170 Finns and 772 non-Finnish Europeans)10. An 
additional 451 CeAD cases of European origin were recruited spe-
cifically for the CADISP-genetics project at European and US centers 
(CADISP-2). These collections provided a total of 1,393 CeAD cases 
of European ancestry for the GWAS (discovery) phase. All CeAD 
cases were ascertained through departments of neurology specialized 
in stroke care (Supplementary Figs. 1–3 and Supplementary Note; 
ClinicalTrials.gov identifier NCT00657969)11. DNA from 14,416 con-
trols was available (287 Finns and 14,129 non-Finnish Europeans). 
We obtained 659 additional CeAD cases that could not be included 
in the GWAS because of the timing of their inclusion or the avail-
ability of only limited amounts of DNA. These cases were used along 
with 2,648 controls for follow-up of a small number of GWAS results. 
Finally, to examine the disease specificity of the genetic associations, we 
recruited 583 individuals with an ischemic stroke attributable to other 
causes (non-CeAD ischemic stroke: 162 Finns and 421 non-Finnish 
Europeans) who had similar age, sex and geographical origin charac-
teristics as the CeAD cases. The clinical characteristics of the research 
subjects are shown in Table 1.
DNA samples were genotyped on an Illumina Human610-Quad 
or Human660W-Quad BeadChip. We performed imputation to the 
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non-monomorphic SNPs described in the HapMap 2 and 1000 Genomes 
Project (August 2010 release) CEU (European-ancestry) panels. 
CADISP-1 and CADISP-2 data were analyzed separately because geno-
typing was carried out on different platforms (Supplementary Table 1). 
Moreover, because Finnish participants had a distinct ancestral origin 
(Supplementary Fig. 4), CADISP-1 was divided into CADISP-1 non-
Finnish and CADISP-1 Finnish studies. We performed a fixed-effects 
inverse variance–weighted meta-analysis after applying a genomic 
control correction to each of the three GWAS results (CADISP-1 non-
Finnish, CADISP-1 Finnish and CADISP-2; Supplementary Note). The 
quantile-quantile plot for the CeAD GWAS is shown in Supplementary 
Figure 5. We observed no overall inflation of P values or evidence for sig-
nificant population stratification (genomic inflation factor λ = 1.032).
A Manhattan plot of the meta-analysis association results for 
genotyped SNPs is shown in Supplementary Figure 6 (and in 
Supplementary Fig. 7 by substudy). The 
evidence of association with CeAD reached 
genome-wide significance for two SNPs at 
two loci. These were rs9349379[G] in intron 2 
of PHACTR1 on chromosome 6p24.1-p23 
(OR = 0.75, 95% CI = 0.69–0.82; P = 4.46 ×  
10−10) and rs11172113[C] in intron 1 of 
LRP1 on chromosome 12q13.3 (OR = 0.78, 
95% CI = 0.71–0.85; P = 4.22 × 10−8). Overall, 
we found 77 SNPs (at 51 loci) with associa-
tion P < 1 × 10−4 (Supplementary Table 2) 
and 6 SNPs (at 5 loci) with association 
P < 1 × 10−5 (Table 2).
We restricted further analyses to loci with 
association P < 1 × 10−5. Two of these SNPs 
showed nominally significant heterogeneity 
in effect according to dissection site (P = 6.49 × 10−3 for rs1466535 
(LRP1) and P = 0.038 for rs6820391 (LNX1)), with stronger asso-
ciations for carotid than vertebral dissection (Table 3). None of 
these markers were associated with non-CeAD ischemic stroke 
(Supplementary Table 3).
We also identified two loci that were not included in the GWAS gen-
otyping panel but reached genome-wide significance when imputed: 
rs2163474 in CCDC102B on chromosome 18q22.1 (OR = 1.78, 95% CI = 
1.50–2.11; P = 3.86 × 10−11) and rs9915775 on chromosome 17q21.1 
(OR = 3.39, 95% CI = 2.21–5.19; P = 1.97 × 10−8). Neither showed 
significant heterogeneity in effect by dissection site (P = 0.72 and 
0.24, respectively), nor were they associated with non-CeAD ischemic 
stroke (Supplementary Table 3). We removed rs9915775 from further 
consideration because of its low estimated minor allele frequency 
(MAF = 0.01) and relatively poor imputation quality (R2 = 0.59).
table 1 Baseline clinical characteristics of the study subjects
CeAD cases
GWAS
Follow-up  
studies
Non-CeAD  
ischemic 
strokeCADISP-1 CADISP-2
n 942 659 583
Mean age (s.d.) 44.2 (10.0) 44.6 (10.5) 43.6 (9.4) 44.6 (10.5)
Men, n (%) 544 (57.7) 264 (58.5) 387 (58.7) 257 (61.2)
Location Carotida, n (%) 603 (64.0) 253 (60.7)b 375 (56.9) –
Vertebral, n (%) 305 (32.4) 147 (35.3)b 256 (38.8) –
Both, n (%) 33 (3.5) 17 (4.0)b 26 (3.9) –
Clinical presentation Cerebral ischemiac, n (%) 729 (77.4) 333 (79.5)b 544 (82.5) –
Ischemic stroke, n (%) 606 (64.3) 281 (67.1)b 508 (77.1) –
CeAD, cervical artery dissection.
aInternal carotid artery dissection (one additional case had a common carotid artery dissection in CADISP-1). bInformation on 
dissection site and associated ischemia was missing for 34 and 32 cases, respectively, in CADISP-2. cCerebral ischemia  
corresponds to ischemic stroke or transient ischemic attack (including transient monocular blindness).
table 2 sNPs yielding the most significant associations with CeAD in the GWAs
SNPa Chr. Position (bp) EA Nearest geneb Stage EAF OR (95% CI) P
rs12402265 1 59,463,190 A FGGY CADISP-1 non-Finnish 0.26 1.21 (1.07–1.36) 2.70 × 10−3
CADISP-1 Finnish 0.28 1.16 (0.87–1.54) 0.315
CADISP-2 0.28 1.28 (1.10–1.49) 1.30 × 10−3
Meta-analysis 1.23 (1.13–1.35) 6.12 × 10−6
rs6741522 2 185,544,143 A ZNF804A CADISP-1 non-Finnish 0.14 1.33 (1.15–1.54) 1.99 × 10−4
CADISP-1 Finnish 0.10 1.32 (0.85–2.05) 0.230
CADISP-2 0.13 1.38 (1.14–1.66) 1.21 × 10−3
Meta-analysis 1.34 (1.19–1.50) 5.65 × 10−7
rs6820391 4 54,109,453 A LNX1 CADISP-1 non-Finnish 0.29 1.21 (1.07–1.36) 2.33 × 10−3
CADISP-1 Finnish 0.29 1.15 (0.86–1.54) 0.345
CADISP-2 0.28 1.26 (1.09–1.47) 2.69 × 10−3
Meta-analysis 1.23 (1.12–1.35) 6.35 × 10−6
rs9349379 6 13,011,943 G PHACTR1 CADISP-1 non-Finnish 0.40 0.76 (0.68–0.86) 8.90 × 10−6
CADISP-1 Finnish 0.45 0.84 (0.63–1.10) 0.216
CADISP-2 0.40 0.73 (0.62–0.84) 3.39 × 10−5
Meta-analysis 0.75 (0.69–0.82) 4.46 × 10−10
rs11172113 12 55,813,550 C LRP1 CADISP-1 non-Finnish 0.38 0.77 (0.68–0.86) 1.66 × 10−5
CADISP-1 Finnish 0.39 0.90 (0.69–1.18) 0.456
CADISP-2 0.40 0.77 (0.67–0.89) 7.61 × 10−4
Meta-analysis 0.78 (0.71–0.85) 4.22 × 10−8
rs1466535c 12 55,820,737 A LRP1 CADISP-1 non-Finnish 0.32 0.75 (0.66–0.85) 1.06 × 10−5
CADISP-1 Finnish 0.28 1.11 (0.83–1.49) 0.473
CADISP-2 0.34 0.80 (0.68–0.93) 4.04 × 10−3
Meta-analysis 0.80 (0.73–0.88) 2.07 × 10−6
Only results for genotyped SNPs with P < 1 × 10−5 are presented here (for all associations with P < 1 × 10−4, see supplementary table 2). Chr., chromosome; EA, effect allele 
(minor allele); EAF, effect allele frequency in controls. Alleles and chromosomal positions were identified on the basis of the plus strand of the NCBI Build 36 reference genome.
ars9349379, rs11172113, rs1466535 and rs6820391 are intronic; rs6741522 and rs12402265 are intergenic. bThe names for the nearest genes are shown according to the Human Gene 
Organization (HUGO) Gene Nomenclature System. crs1466535 is in LD with rs11172113 (r2 = 0.72).
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We examined 6 SNP markers at the 5 most significantly associated 
loci from the genotyped panel (P < 1 × 10−5 in the GWAS) in the 
659 CeAD case and 2,648 control samples available for follow-up 
(Supplementary Table 4). In addition, we selected two SNPs from 
the imputed locus at 18q22.1 for genotyping in follow-up samples 
(Supplementary Table 5). We also genotyped two proxies for two of 
the most significantly associated SNPs from the GWAS meta-analysis 
(rs12215208, r2 = 0.39 with rs9349379; rs6761601, r2 = 0.67 with 
rs6741522).
First, we calculated association statistics for the follow-up samples, 
using a threshold of P = 5.00 × 10−3 to assign significance (Bonferroni 
correction for ten SNPs; a conservative threshold because of the exist-
ence of positive linkage disequilibrium (LD) between some markers); 
irrespective of significance, we calculated combined association test 
statistics using meta-analysis and evaluated evidence of heterogeneity 
between the GWAS and follow-up data (Table 3 and Supplementary 
Table 5). Second, we applied a Bayesian approach to evaluate the 
significance of the associations using Wakefield’s approximate Bayes 
factor (Online Methods)12. Asymptotic Bayes factor (ABF) and 
Bayesian false discovery probability (BFDP) values are provided in 
Supplementary Tables 6 and 7.
rs9349379 (in PHACTR1), which provided the strongest evidence 
of association in the GWAS data, showed significant association 
with CeAD in the follow-up sample using the Bonferroni-corrected 
P-value threshold described above (P = 5.00 × 10−3), and the result 
from the meta-analysis of the discovery and follow-up studies main-
tained the finding of genome-wide significance (OR = 0.77, 95% CI = 
0.72–0.83; P = 1.00 × 10−11) (Fig. 1 and Supplementary Fig. 8). 
table 3 sNPs yielding the most significant associations with CeAD and their proxies in GWAs and follow-up studies 
SNP Chr. EA EAF Gene
CeAD  
site
Phet  
CeAD siteb
GWAS meta-analysis Follow-up meta-analysis Overall meta-analysis
(n = 1,393/14,416) (n = 659/2,648) (n = 2,052/17,064)
OR  
(95% CI) P
OR  
(95% CI) P
OR  
(95% CI) P Phet
rs12402265a 1 A 0.27 FGGY All 0.70 1.23 
(1.13–1.35)
6.12 × 10−6 1.21 
(1.04–1.40)
0.012 1.23 
(1.14–1.33)
2.30 × 10−7 0.83
Carotid 1.23 
(1.10–1.38)
2.95 × 10−4 1.40 
(1.17–1.68)
2.52 × 10−4 1.28 
(1.16–1.41)
5.46 × 10−7 0.24
Vertebral 1.27 
(1.10–1.47)
1.36 × 10−3 1.05 
(0.85–1.31)
0.64 1.20 
(1.06–1.35)
3.47 × 10−3 0.16
rs6741522 2 A 0.13 ZNF804A All 0.64 1.34 
(1.19–1.50)
5.65 × 10−7 1.09 
(0.91–1.31)
0.36 1.26 
(1.15–1.39)
2.29 × 10−6 0.06
Carotid 1.37 
(1.19–1.57)
1.17 × 10−5 1.05 
(0.83–1.32)
0.68 1.27 
(1.13–1.44)
7.33 × 10−5 0.06
Vertebral 1.32 
(1.10–1.60)
3.53 × 10−3 1.24 
(0.96–1.61)
0.10 1.29 
(1.11–1.51)
8.92 × 10−4 0.69
rs6820391 4 A 0.29 LNX1 All 0.038 1.23 
(1.12–1.35)
6.35 × 10−6 1.28 
(1.10–1.47)
9.28 × 10−4 1.24 
(1.15–1.34)
2.36 × 10−8 0.68
Carotid 1.30 
(1.16–1.45)
3.88 × 10−6 1.29 
(1.08–1.55)
4.84 × 10−3 1.30 
(1.18–1.43)
6.41 × 10−8 0.97
Vertebral 1.09 
(0.94–1.26)
0.28 1.23 
(1.00–1.52)
0.049 1.13 
(1.00–1.28)
0.042 0.33
rs9349379 6 G 0.40 PHACTR1 All 0.52 0.75 
(0.69–0.82)
4.46 × 10−10 0.81 
(0.71–0.94)
3.91 × 10−3 0.77 
(0.72–0.83)
1.00 × 10−11 0.36
Carotid 0.76 
(0.68–0.85)
1.27 × 10−6 0.76 
(0.64–0.90)
1.79 × 10−3 0.76 
(0.69–0.83)
8.24 × 10−9 0.96
Vertebral 0.72 
(0.62–0.84)
1.38 × 10−5 0.92 
(0.75–1.13)
0.42 0.79 
(0.70–0.88)
6.32 × 10−5 0.06
rs11172113 12 C 0.39 LRP1 All 0.061 0.78 
(0.71–0.85)
4.22 × 10−8 0.93 
(0.81–1.07)
0.34 0.82 
(0.76–0.89)
3.03 × 10−7 0.03
Carotid 0.74 
(0.66–0.83)
1.14 × 10−7 0.88 
(0.75–1.05)
0.16 0.78 
(0.71–0.86)
1.90 × 10−7 0.08
Vertebral 0.89 
(0.77–1.03)
0.11 0.99 
(0.81–1.21)
0.93 0.92 
(0.82–1.04)
0.17 0.39
rs1466535a 12 A 0.32 LRP1 All 6.49 × 10−3 0.80 
(0.73–0.88)
2.07 × 10−6 0.92 
(0.80–1.07)
0.30 0.83 
(0.77–0.90)
4.94 × 10−6 0.10
Carotid 0.73 
(0.65–0.82)
2.50 × 10−7 0.85 
(0.71–1.01)
0.07 0.76 
(0.69–0.84)
1.17 × 10−7 0.18
Vertebral 0.97 
(0.84–1.12)
0.68 0.99 
(0.80–1.22)
0.92 0.98 
(0.87–1.10)
0.69 0.87
Chr., chromosome; EA, effect allele (minor allele); EAF, effect allele frequency (in controls from the GWAS); OR, odds ratio; CI, confidence interval; Phet, P value for heterogeneity 
between the discovery GWAS and the follow-up sample.
aThese SNPs were imputed (HapMap 2) in the Maryland follow-up sample with R2 = 0.93 (rs1466535) and 1 (rs12402265). bThe P value of association with the dissection site in a case-only 
analysis.
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Application of the Wakefield Bayesian 
approach yielded an ABF of 1.70 × 10−10. 
Another SNP in PHACTR1, rs12215208, 
selected as a proxy (P = 2.52 × 10−5 in the 
GWAS), exhibited a nominally signifi-
cant association in the follow-up samples 
(P = 0.015), but the combined GWAS and 
follow-up data did not show genome-wide 
significant association (Supplementary 
Table 5). In contrast, we found no evidence of association in 
follow-up samples at rs11172113 in LRP1, the second genotyped 
marker that had genome-wide significant association in the GWAS 
(Supplementary Fig. 8).
Of the other markers that we examined, one met the criteria for 
significance in the follow-up samples: rs6820391 in LNX1 on chromo-
some 4q12 gave P = 9.28 × 10−4 in the follow-up samples and reached 
genome-wide significance in the combined meta-analysis (OR = 
1.24, 95% CI = 1.15–1.34; P = 2.36 × 10−8) (Supplementary Fig. 8). 
However, as the Wakefield Bayesian approach yielded an ABF of 3.25 × 
10−6, we consider this association to be only suggestive, requiring 
further studies for confirmation. Data for the imputed 18q22.1 locus 
provided no evidence in favor of association in the follow-up collec-
tion (P > 0.15; Supplementary Table 5).
In sensitivity analyses, stratifying on sex, migraine status and recent 
cervical trauma status did not modify the genetic associations with 
CeAD for the top loci (Supplementary Tables 8–10). We observed a 
nominally significant association of the rs9349379 (PHACTR1) risk allele 
for CeAD with a younger age of onset (Supplementary Table 11). The 
effect of rs9349379 was more marked in individuals with CeAD without 
ischemia, whereas the effect of rs6820391 (LNX1) was more marked in 
individuals with CeAD with ischemia, although the confidence intervals 
largely overlapped and P values were similar (Supplementary Table 12). 
Secondary analyses of association performed separately for carotid and 
vertebral artery dissections did not yield any genome-wide significant 
association (Supplementary Table 13).
We did not find any association with CeAD for (i) SNPs reported 
to be associated with CeAD in candidate gene association studies13–15; 
(ii) SNPs within a 100-kb window from the start and end of COL3A1, 
the gene harboring causal mutations for vascular Ehlers-Danlos syn-
drome, a rare etiology of CeAD16; and (iii) published genome-wide 
susceptibility SNPs for intracranial aneurysms17–19 and for thoracic 
aortic aneurysms and dissection20 (Supplementary Tables 14–17).
Our most significant association with CeAD was for rs9349379 
(PHACTR1), which has been associated with myocardial infarc-
tion and coronary calcifications in various ancestry groups6,7,21–26, 
with effects in the opposite direction of that in CeAD. Two other 
susceptibility loci for myocardial infarction showed significant 
associations with CeAD in our data set with effects in the oppo-
site direction of those for CeAD (rs2023938 (HDAC9)7 and 
rs9982601 (SLC5A3, MRPS6 and KCNE2)6), and one susceptibility 
locus for myocardial infarction at 9p21 was associated with CeAD 
with the same direction of effect (rs3217992 (CDKN2B-AS1)7) 
(Supplementary Table 18). No significant association was found 
between rs9349379 and non-CeAD ischemic stroke in our data 
set, although such an association was recently described in a larger 
sample for the ischemic stroke subtype secondary to large artery athero-
sclerosis (LAA-IS), where the effect was in the opposite direction to the 
one we observed for CeAD27. Another variant predisposing to LAA-IS 
(rs11984041 (HDAC9)28,29; r2 = 1 with rs2023938) also displayed an 
inverse association with CeAD (Supplementary Table 19). Opposite 
effects of the same genetic variant on different diseases have been 
described elsewhere30 and suggest either that the same region harbors 
different causal variants or that the same causal variant has biological 
effects with opposite implications for each disease. The vascular 
risk factor profile3,4, young age of occurrence1 and heterogeneous 
echostructure of carotid arteries in individuals with CeAD31 all 
suggest that atherosclerosis is not a predisposing condition for CeAD, 
in contrast with aortic dissection32. With aging and arteriosclerosis, 
the increased synthesis and reduced degradation of extracellular 
matrix components, as well as increasing collagen and elastin cross-
links, could be hypothesized to make the arterial walls of cervical arter-
ies more resistant to tears33,34, as could arterial wall calcifications, thus 
rendering the artery more stiff and resistant to the shear forces of 
lateral rotation and hyperextension that contribute to CeAD35.
Migraine is more common in individuals with CeAD than in the 
community1,2, and vascular mechanisms are thought to have a key 
role in the pathophysiology of this disease36. Recently, rs9349379 
(PHACTR1) and rs11172113 (LRP1) were identified as migraine sus-
ceptibility SNPs8,9,37. Moreover, one additional migraine risk variant 
(rs13208321 in FHL5)9 was associated with CeAD at P = 6.80 × 10−4. 
All these SNPs showed effects in the same direction as those for CeAD 
(Supplementary Table 20). Interestingly, associations with these 
shared variants were most significant for migraine without aura9, the 
migraine subtype most commonly associated with CeAD38.
PHACTR1 is in a highly conserved genomic region, suggesting that 
it has a crucial involvement in biological processes39, but its function 
is poorly understood. Experimental studies identified a pivotal role 
for the PHACTR1 protein in vascular tube formation and actin 
polymerization, suggesting that it possibly has a role in angiogenic 
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Figure 1 Regional association plot centered 
on rs9349379 (PHACTR1). Regional plot 
for associations in the region centered 
on rs9349379, drawn using LocusZoom 
software49. All SNPs, on the basis of 1000 
Genomes Project imputed results (dots), 
are plotted with their GWAS meta-analysis 
association P values against their genomic 
position. The color of the dots represents the LD 
between SNPs. The purple line represents the 
estimated recombination rates. Genes and exons 
are shown as dark blue arrows and vertical lines, 
respectively.
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processes40,41. Upregulation of PHACTR1 by transforming growth factor 
(TGF)-β has been described in breast cancer cell lines42, potentially 
pointing to a connection with the TGF-β signaling pathway, which is 
also implicated in genetic predisposition to migraine9 and has a key 
role in Marfan and Loeys-Dietz syndromes, two inherited connective 
tissue disorders causing aortic dissection43,44. In silico functional 
annotation obtained from a wide array of published and unpublished 
expression quantitative trait locus (eQTL) data sets (Supplementary 
Table 21) provides some support for a functional effect of CeAD-
associated SNPs in the 6p24.1-p23 locus on PHACTR1 expression in 
whole blood and cerebellum cells (although the SNPs in the databases 
are in relatively weak LD with rs9349379)45,46.
Although the follow-up analysis did not provide additional support 
for association with markers in LRP1, this locus remains of interest 
because of its association with migraine and abdominal aortic aneu-
rysm, with effects in the same direction as in CeAD (Supplementary 
Table 17)47.
CeAD is relatively uncommon (~2.6/100,000 cases per year)48, and 
the current study is by far the largest genetic study of CeAD thus far 
(2,052 CeAD cases). Nevertheless, we might have lacked power to 
detect and replicate some associations, especially for loci showing 
heterogeneity in effect according to dissection site (Supplementary 
Table 22). We deliberately chose to focus on the discovery of genetic 
variants with overarching effects on CeAD risk, as we were underpow-
ered to identify genetic variants underlying carotid or vertebral dis-
section exclusively. Future studies on larger samples are warranted to 
explore specific genetic susceptibility factors for carotid and vertebral 
artery dissections and to determine whether the 12q13.3 (LRP1), 4q12 
(LNX1) and 18q22.1 (CCDC102B) loci are associated with CeAD.
In summary, we identified one previously unreported genome-wide 
significant risk locus for CeAD at PHACTR1 and additional highly 
suggestive loci requiring confirmation in future independent studies. 
PHACTR1 is also a major susceptibility locus for myocardial infarction 
and migraine. Understanding the mechanisms by which this locus 
appears to influence key vascular functions could have major applica-
tions for the treatment of these severe and disabling conditions.
URLs. CADISP, http://www.cadisp.com/; International Stroke 
Genetics Consortium, http://www.strokegenetics.org/.
MeThODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Study population. CeAD cases. We included 942 CeAD cases in the CADISP 
study in 2004–2009 (CADISP-1: 170 Finns and 772 non-Finnish Europeans)10. 
An additional 451 CeAD cases of European origin were recruited in 2008–
2010, exclusively for the CADISP-genetics project, in some CADISP centers 
and additional European and US centers (CADISP-2). In total, 1,393 CeAD 
cases of European ancestry were available. All CeAD cases were ascertained 
through departments of neurology specialized in stroke care. Inclusion criteria, 
recruiting centers and participant selection are described in Supplementary 
Figures 1–3 and the Supplementary Note11.
Individuals with non-CeAD ischemic stroke. As most individuals with 
CeAD sustained a cerebral ischemia, we planned to test whether genetic 
variants associated with CeAD were specific for CeAD, possibly through a 
predisposing vasculopathy, and did not confer generalized susceptibility to 
cerebral ischemia in young adults that could also predispose to other sub-
types of ischemic stroke. We recruited 583 individuals with an ischemic stroke 
attributable to other causes (non-CeAD ischemic stroke: 162 Finns and 421 
non-Finnish Europeans), frequency matched on the basis of age, sex and 
geographical origin to the CADISP-1 CeAD cases (Supplementary Fig. 3 and 
Supplementary Note).
Control populations. DNA for 14,416 controls was available. Most controls 
(n = 14,203: 74 Finns and 14,129 non-Finnish Europeans) were selected 
from an anonymized control genotype database at the CNG (Centre National 
de Génotypage) to match cases for ancestry, on the basis of the distribution 
of eigenvectors (Supplementary Fig. 4 and Supplementary Note)50. In 
addition, 213 Finnish controls were recruited (Supplementary Note). 
Although controls were not screened for CeAD, given the low disease 
incidence in the community, a misclassification bias is unlikely.
Genotyping, quality control filters and imputation. DNA samples were 
genotyped on an Illumina Human610-Quad or Human660W-Quad BeadChip 
(Supplementary Table 1 and Supplementary Note). After quality control 
(Supplementary Note), we used 472,862 autosomal SNPs and 10,029 
X-chromosomal SNPs for analyses. We performed genotype imputation to the 
non-monomorphic SNPs described in the HapMap 2 and 1000 Genomes 
Project (August 2010 release) CEU panels (Supplementary Note). Only 
SNPs with an imputation score of R2 > 0.3 and a MAF of >0.01 were used 
for analysis.
Follow-up studies. We sought to replicate our strongest association signals in 
an independent sample comprising 659 CeAD cases, mostly drawn from exist-
ing databases of ischemic stroke (recruited through neurology departments 
specialized in stroke care according to the same inclusion criteria as in the 
discovery GWAS), and 2,648 controls, all of European ancestry (Supplementary 
Table 4). Some of these (85 CeAD cases and 998 controls) had already been 
genotyped elsewhere on a genome-wide chip (Supplementary Table 1 and 
Supplementary Note). In addition, DNA samples from 238 CeAD cases 
were genotyped across the genome, and 1,584 controls were genotyped on 
a custom chip including the SNPs yielding the most significant associations 
in the GWAS (Supplementary Table 1 and Supplementary Note). Finally, 
DNA samples from 391 additional CeAD cases and 162 controls, recruited in 
the same centers as other individuals included in the discovery or follow-up 
analyses, were genotyped for the top 5 genotyped loci and the top imputed 
locus (1–2 SNPs per locus) using KASPAR technology. Of these 714 follow-up 
CeAD cases, 55 were excluded because of the unavailability of information 
on the dissection site, leaving us with 659 CeAD cases for analysis. To avoid 
population stratification bias, the association of the top SNPs with CeAD 
was analyzed separately by inclusion region (see Supplementary Table 4 for 
the matching algorithm), and meta-analysis (fixed effects, inverse variance 
weighted) was performed on the results.
Statistics. Genome-wide association analysis comparing CeAD cases to healthy 
controls. Analyses were based on an additive genetic model. We used logistic 
regression to estimate OR values with corresponding 95% CIs, adjusting for 
sex. The CADISP-1 and CADISP-2 cohorts were analyzed separately because 
genotyping was carried out on different platforms (Supplementary Table 1). 
Moreover, because Finnish participants had a distinct ancestral origin relative 
to other populations (Supplementary Fig. 4), CADISP-1 was divided into 
CADISP-1 non-Finnish and CADISP-1 Finnish cohorts. Hence, sample sizes 
(CeAD-cases/controls) were as follows: 772/8,972 for CADISP-1 non-Finnish, 
170/287 for CADISP-1 Finnish and 451/5,157 for CADISP-2. The first ten 
principal component scores were used as covariates for the CADISP-1 non-
Finnish and CADISP-2 cohorts, and the first principal component score was 
used for the CADISP-1 Finnish cohort (Supplementary Note). Genomic 
control was applied to each of the three GWAS results (CADISP-1 non-
Finnish, CADISP-1 Finnish and CADISP-2). Thereafter, a combined analysis 
was performed by inverse variance–weighted meta-analysis with a fixed-effects 
model (Supplementary Note). P < 5 × 10−8 was considered genome-wide 
significant.
Follow-up study. Because of the limits on DNA availability, six loci (ten 
SNPs) were chosen for follow-up genotyping in the phase 3 samples uniquely 
on the basis of statistical rankings in the GWAS meta-analysis of phase 1 and 
2 samples (CADISP-1 and CADISP-2). We examined 6 SNP markers at the 
5 most significantly associated loci from the genotyped panel (P < 1 × 10−5 in 
the GWAS) in the 659 CeAD and 2,648 control samples available for follow-up. 
In addition, two SNPs from the imputed locus on chromosome 18q22.1 were 
selected for genotyping in follow-up samples (Supplementary Table 5). 
We also genotyped two proxies for two of the most significantly associated 
SNPs (P < 1 × 10−5) from the GWAS meta-analysis (rs12215208, r2 = 0.39 with 
rs9349379; rs6761601, r2 = 0.67 with rs6741522).
First, we calculated the association statistics for the follow-up samples, using 
a threshold of P = 5.00 × 10−3 to assign significance (with Bonferroni correc-
tion for ten SNPs, which is conservative because of positive LD between some 
markers); irrespective of significance, we calculated combined association test 
statistics using meta-analysis and evaluated evidence of heterogeneity between 
GWAS and follow-up data. Second, we applied a Bayesian approach to evaluate 
the significance of associations using Wakefield’s approximate Bayes factor12. 
ABF and BFDP values are provided in Supplementary Tables 6 and 7.
Bayesian approach. We followed the approach developed by Wakefield12 to 
consider the posterior odds on the null hypothesis (no association of a SNP 
with CeAD) for sequential studies from a Bayesian perspective. In summary, 
we obtained estimates of the log relative risk qˆ , standard error V and Wald 
statistic ˆ /ˆa z V2 2= q  for a SNP from the logistic regression model (based on an 
additive genetic model), which was performed as our primary analysis to gen-
erate frequentist P values (Table 3 and Supplementary Table 5). Thereafter, 
we calculated Wakefield’s ABF as follows:
ABF = − + +( ){ }WRVV z RV z z R V V z RV1 2 12 2 1 2 1 2 22 112 2exp
where W is the variance on the prior for the effect size, R=W/(V1W+V2W+V1V2), 
V1 and V2 are squared standard errors, and z1 and z2 are Wald statistics, each 
from the discovery GWAS (stages 1 and 2 combined) and the follow-up study 
(stage 3). A smaller ABF value corresponds to more evidence of the alternative 
hypothesis, i.e., the association of a SNP with CeAD.
Wakefield proposed three different specifications of priors for the log 
relative risk. Because our aim in this study was to find common suscep-
tibility variants for CeAD, we followed an effect-MAF independence 
prior as W qu= −( ){ }−log /RR Φ 1 21 , with RRu = 1.5. RRu is an upper value 
above which we believe that relative risks will occur with low probability; 
q is the prior probability of a relative risk above RRu; Φ (.) is the distribution 
function of a standard normal random variable.
Considering PO = π0/(1– π0) to be the prior odds on the null hypothesis, 
where π0 is the prior probability of the null (Pr[H0]), the posterior probability 
of H0 is given by the BFDP, with BFDP = ABF × PO/(1 + ABF × PO).
Specificity analysis. We tested whether the SNPs yielding the most signifi-
cant associations with CeAD were also associated with non-CeAD ischemic 
stroke. We ran a logistic regression adjusted for sex and principal components, 
as described above, for non-Finnish Europeans (421 cases and 8,972 controls) 
and Finns (162 cases and 287 controls), followed by a fixed-effects inverse 
variance–weighted meta-analysis. Statistical significance was defined by false 
discovery rate (FDR)-corrected P < 0.05.
Sensitivity analyses. For the most significant associations, we stratified 
on and tested for interaction with sex, and we examined whether the most 
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significant SNPs predicted an earlier age of onset of CeAD. We then evaluated 
the stability of the associations according to dissection site (carotid or 
vertebral) and the presence of cerebral ischemia (ischemic stroke or transient 
ischemic attack). Finally, we performed analyses stratified on the presence 
of two CeAD risk factors, migraine and cervical trauma in cases; case-only 
association analyses of the top CeAD SNPs with dissection site, the presence 
of cerebral ischemia, migraine and trauma were used as surrogate tests of 
heterogeneity or interaction, with P < 0.05 being considered significant51.
Candidate gene approach. We examined the associations of CeAD with 
published CeAD susceptibility SNPs and with SNPs in COL3A1, the gene 
harboring causal mutations for vascular Ehlers-Danlos syndrome, a rare 
etiology of CeAD16. We also tested for pleiotropic effects of susceptibility 
SNPs for intracranial aneurysms, thoracic aortic aneurysms and dissections, 
other subtypes of ischemic stroke and migraine (Supplementary Note). 
An FDR-corrected P value of <0.05 was considered to be statistically significant. 
We performed a sign test to evaluate whether associations of CeAD with alleles 
previously associated with migraine and ischemic stroke subtypes involved the 
same risk alleles more often than predicted by chance. A right-tailed P value 
of 0.05 was considered to be statistically significant.
Ethics. The study protocol was approved by local authorities in all partici-
pating centers and conducted according to national rules concerning ethics 
committee approval and informed consent.
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